Pan-HER antibody composition

摘要

The present invention is directed to improved therapeutics against receptors within the EGFR/ErbB/HER family that more broadly interfere with multiple members of the HER family (pan-HER inhibition). More particularly, the invention is directed to the use of antibody compositions for human cancer therapy. In vitro studies have shown that the antibody compositions of the invention targeting multiple HER family receptors are superior to antibody compositions targeting only one HER family receptor.

主权项

1. A pharmaceutical antibody composition comprising one or two distinct anti-EGFR antibody molecules, one or two distinct anti-HER2 antibody molecules, and one or two distinct anti-HER3 antibody molecules, wherein:
a) the one or two distinct anti-EGFR antibody molecules each are capable of inhibiting the binding of, and/or bind to the same epitope as, an antibody comprising the heavy and light chain variable domain (VH and VL) amino acid sequences in SEQ ID NOs: 18 and 20, respectively SEQ ID NOs: 22 and 24, respectively; or SEQ ID NOs: 14 and 16, respectively; b) the one or two distinct anti-HER2 antibody molecules each are capable of inhibiting the binding of, and/or bind to the same epitope as, an antibody comprising the VH and VL amino acid sequences in SEQ ID NOs: 30 and 32, respectively; SEQ ID NOs: 34 and 36, respectively; SEQ ID NOs: 38 and 40, respectively; or SEQ ID NOs: 42 and 44, respectively; or c) the one or two distinct anti-HER3 antibody molecules each are capable of inhibiting the binding of, and/or bind to the same epitope as, an antibody comprising the VH and VL amino acid sequences in SEQ ID NOs: 50 and 52, respectively; or SEQ ID NOs: 54 and 56, respectively.